GIOTRIF® :
The 1^st choice in 1^st-line

Superior efficacy vs gefitinib and vs chemotherapy
demonstrated in 3 large trials in 1^st-line EGFR M+ NSCLC^1-4*

GIOTRIF® followed by 3rd generation TKI in GioSwing Sequential Cohort (Combined Analysis of Two Global Non-Interventional Studies)

Document ID: PC-MY-102737

14/10/2022

Author: Boehringer Ingelheim

123,000
Views

100k 340